Here Comes Sun's US Cost-Saver Gleevec Generic

Sun Pharma has launched its generic version of Novartis' blockbuster anticancer Gleevec (imatinib mesylate) in the US at a savings of around 30%, putting the spotlight on the specialty segment which is probably, for the first time, witnessing genericization of such a high cost therapy.